title: A novel onco-miR-365 induces cutaneous squamous cell carcinoma.
abstract: The expression levels of miR-365 vary in different malignancies. Herein, we found that miR-365 was overexpressed in both cells and clinical specimens of cutaneous squamous cell carcinoma (SCC). We demonstrated that the HaCaT(pre-miR-365-2) cell line, which overexpressed miR-365, could induce subcutaneous tumors in vivo. Antagomir-365, an anti-miR-365 oligonucleotide, inhibited cutaneous tumor formation in vivo, along with G1 phase arrest and apoptosis of cancer cells. These findings suggest that miR-365 may act as an onco-miR in cutaneous SCC both in vitro and in vivo. The present study provides valuable insight into the role of miR-365 in cutaneous SCC formation, which can help develop new drug and miR-365 target-based therapies for cutaneous SCC.
authors.affiliation: Department of Radiation Medicine, School of Public Health and Tropic Medicine, Southern Medical University, Guangdong, Guangzhou 510515, People's Republic of China.
authors.forename: Meijuan
authors.initials: M
authors.lastname: Zhou
authors.forename: Weilin
authors.initials: W
authors.lastname: Liu
authors.forename: Shudong
authors.initials: S
authors.lastname: Ma
authors.forename: Hong
authors.initials: H
authors.lastname: Cao
authors.forename: Xuebiao
authors.initials: X
authors.lastname: Peng
authors.forename: Ling
authors.initials: L
authors.lastname: Guo
authors.forename: Xinhua
authors.initials: X
authors.lastname: Zhou
authors.forename: Li
authors.initials: L
authors.lastname: Zheng
authors.forename: Linlang
authors.initials: L
authors.lastname: Guo
authors.forename: Miaojian
authors.initials: M
authors.lastname: Wan
authors.forename: Weimin
authors.initials: W
authors.lastname: Shi
authors.forename: Yingjie
authors.initials: Y
authors.lastname: He
authors.forename: Chao
authors.initials: C
authors.lastname: Lu
authors.forename: Lihong
authors.initials: L
authors.lastname: Jiang
authors.forename: Chengshan
authors.initials: C
authors.lastname: Ou
authors.forename: Yuanxia
authors.initials: Y
authors.lastname: Guo
authors.forename: Zhenhua
authors.initials: Z
authors.lastname: Ding
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D017209:Apoptosis; D002294:Carcinoma, Squamous Cell / Q000235:genetics* / Q000473:pathology / Q000628:therapy; D045744:Cell Line, Tumor; D005260:Female; D059585:G1 Phase Cell Cycle Checkpoints; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D035683:MicroRNAs / Q000235:genetics / Q000378:metabolism*; D008875:Middle Aged; D009367:Neoplasm Staging; D009368:Neoplasm Transplantation / Q000473:pathology; D020320:Oligoribonucleotides, Antisense / Q000008:administration & dosage; D012334:RNA, Neoplasm / Q000235:genetics / Q000378:metabolism*; D012878:Skin Neoplasms / Q000235:genetics* / Q000473:pathology
chemical_list: D000970:Antineoplastic Agents; C546819:MIRN365 microRNA, human; D035683:MicroRNAs; D020320:Oligoribonucleotides, Antisense; D012334:RNA, Neoplasm